EASD 2013:胰岛素与死亡风险之间有剂量效应关系

2013-09-29 desperado-c dxy

最近出现的流行病学数据连同临床和生物学论据一起, 提出关于2型糖尿病患者广泛使用外源性胰岛素的问题。目前缺少专门设计的随机试验。为了探讨胰岛素是否增加2型糖尿病患者的死亡风险,以及两者之间是否存在剂量反应关系。来自英国卡迪夫大学Craig Currie教授及其团队进行了一项研究,该研究发现2型糖尿病患者胰岛素与死亡风险之间有剂量效应关系。该研究结果发布在2013年EASD会议上。该研究中,数据来自

最近出现的流行病学数据连同临床和生物学论据一起, 提出关于2型糖尿病患者广泛使用外源性胰岛素的问题。目前缺少专门设计的随机试验。为了探讨胰岛素是否增加2型糖尿病患者的死亡风险,以及两者之间是否存在剂量反应关系。来自英国卡迪夫大学Craig Currie教授及其团队进行了一项研究,该研究发现2型糖尿病患者胰岛素与死亡风险之间有剂量效应关系。该研究结果发布在2013年EASD会议上。

该研究中,数据来自临床试验研究数据集中10%的英国人群样本。使用严格的数据质量标准,挑选已经发展到需要使用胰岛素治疗的2型糖尿病患者。第一份胰岛素处方作为索引数据。通过处方记录量评估平均每年根据体重处方的胰岛素剂量。评价指标为全因死亡率和Cox模型评估的由常见危险因素导致的死亡风险。把胰岛素剂量当作一个时间依赖性变量进行评估。胰岛素剂量被分为≤0.5、>0.5并≤1.0、>1.0并≤1.5、和>1.5iu/kg/天,并用最小剂量作对照。【原文下载

该研究结果表明,确定了8414例患者使用单用胰岛素方案,并接受至少两次连续胰岛素处方。这些患者中,7538例患者有完整的胰岛素剂量(平均剂量≤4iu/kg/天)、体重和实时事件信息;1年内分别将2193例、3818例、1013例和514例患者分到≤0.5、>0.5并≤1.0、>1.0并≤1.5、和>1.5iu/kg/天胰岛素剂量组。基线整体平均年龄分别为64.6、64.7、64.4或 64.9岁,男性分别占63%、55%、51%和47%;并且每增加一个剂量类别,基线平均HbA1c分别为9.2%、9.7%、9.9%和9.6%。HbA1c最小五分位数的患者死亡风险增加,且胰岛素剂量在1.0iu/kg/天以上患者,死亡风险有普遍增加模式。这种剂量相关模式与大量表型(例如基线良好血糖控制的患者)亚组相一致。与小剂量胰岛素组相比(≤0.5iu/kg/天)相比,年龄≤55岁、>55并≤65、>65并≤75、和>75岁大剂量胰岛素组(>1.5iu/kg/天)患者校正风险比为1.36、1.43、2.04和2.89。

该研究发现,2型糖尿病患者胰岛素与死亡风险之间有剂量效应关系。那些进展到需要胰岛素治疗,且血糖控制良好的老年患者风险特别高。

原文下载


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749437, encodeId=b37c1e494370a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Nov 14 13:59:00 CST 2013, time=2013-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690567, encodeId=9841169056e13, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Nov 24 23:59:00 CST 2013, time=2013-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255455, encodeId=47a8125545507, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534061, encodeId=1baf153406145, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
    2013-11-14 baoya
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749437, encodeId=b37c1e494370a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Nov 14 13:59:00 CST 2013, time=2013-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690567, encodeId=9841169056e13, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Nov 24 23:59:00 CST 2013, time=2013-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255455, encodeId=47a8125545507, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534061, encodeId=1baf153406145, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
    2013-11-24 okhuali
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749437, encodeId=b37c1e494370a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Nov 14 13:59:00 CST 2013, time=2013-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690567, encodeId=9841169056e13, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Nov 24 23:59:00 CST 2013, time=2013-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255455, encodeId=47a8125545507, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534061, encodeId=1baf153406145, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1749437, encodeId=b37c1e494370a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Nov 14 13:59:00 CST 2013, time=2013-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690567, encodeId=9841169056e13, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun Nov 24 23:59:00 CST 2013, time=2013-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255455, encodeId=47a8125545507, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534061, encodeId=1baf153406145, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Tue Oct 01 08:59:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
    2013-10-01 qilu_qi